Alpha-particle emitters display high linear energy transfer combined with short range and are promising for treatment of tumor micrometastases. Indeed, efficiency and high specificity of tumor-specific antibodies labeled with alpha emitting nuclides were described in vitro and in vivo. Radiolabeled somatostatin analogues with high affinity to somatostatin receptor overexpressing tumors are an attractive option for peptide-receptor radionuclide therapy of metastasized neuroendocrine tumors and great clinical success has been demonstrated with Lutetium-177 as therapeutic isotope.
In this study, we investigated cellular effects of alpha-particle emitter Actinium-225 in comparison to beta-particle emitter Lutetium-177 labeled somatostatin analogue DOTATOC in vitro and in vivo. Cellular studies were performed in p53 dependent and somatostatin receptor expressing rat pancreatic acinar carcinoma AR42J cells.
GRAF Franziska;
FAHRER Jörg;
MAUS Stephan;
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
VENKATACHALAM S.;
FOTTNER C.;
WEBER Matthias M.;
HUELSENBECK Johannes;
SCHRECKENBERGER M;
KAINA B;
MIEDERER Matthias;
2013-12-18
SPRINGER
JRC80827
1619-7070,
https://publications.jrc.ec.europa.eu/repository/handle/JRC80827,
10.1007/s00259-013-2535-3,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|